SCHEMBL19744673

SCHEMBL19744673

CC(C)(C)OC(=O)NC(CC1CCCCC1)C(=O)N1CCC[C@H]1C(=O)O

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CTSS P25774 2/20 0.56
CTSK P43235 2/20 0.56
ACE P12821 7/20 0.53
CMA1 P23946 1/20 0.46
REN P00797 4/20 0.43
KDM4E B2RXH2 1/20 0.43
F2 P00734 1/20 0.43
LMNA P02545 1/20 0.43
LTA4H P09960 1/20 0.43
MAPT P10636 1/20 0.43
PEPD P12955 1/20 0.43
ALOX15 P16050 1/20 0.43
PTGS1 P23219 1/20 0.43
HTR2A P28223 1/20 0.43
PTGS2 P35354 1/20 0.43
HRH1 P35367 1/20 0.43
THPO P40225 1/20 0.43
PMP22 Q01453 1/20 0.43
HSD17B10 Q99714 1/20 0.43
ACE2 Q9BYF1 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19744672 1.00 CTSS (0.56) CTSSCTSKACECMA1REN
SCHEMBL21536111 0.90 CTSK (0.53) CTSSCTSKACECMA1F2
SCHEMBL28286258 0.90 CTSK (0.53) CTSSCTSKACECMA1F2
SCHEMBL22070275 0.86 ACE (0.57) ACECMA1RENKDM4EF2
SCHEMBL22070276 0.86 ACE (0.57) ACECMA1RENKDM4EF2
SCHEMBL6242285 0.86 ACE (0.57) CTSSCTSKACECMA1REN
SCHEMBL7563228 0.85 ACE (0.56) ACECMA1RENKDM4EF2
SCHEMBL7383100 0.85 ACE (0.48) ACERENKDM4EF2LMNA
SCHEMBL23795534 0.84 ACE (0.55) ACECMA1RENKDM4EF2
SCHEMBL23795536 0.84 ACE (0.55) ACECMA1RENKDM4EF2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-109563033-B Aliphatic prolinamide derivatives 奥瑞恩眼科有限责任公司 2023-04-04 CN disclosed
EP-3472130-B1 ALIPHATIC PROLINAMIDE DERIVATIVES Orion Ophthalmology LLC (US) 2022-02-16 EP disclosed
US-10730832-B2 Aliphatic prolinamide derivatives Orion Ophthalmology LLC (US) 2020-08-04 US disclosed
US-20190330146-A1 ALIPHATIC PROLINAMIDE DERIVATIVES Orion Ophthalmology LLC (US) 2019-10-31 US disclosed
EP-3472130-A1 ALIPHATIC PROLINAMIDE DERIVATIVES ORION OPTHALMOLOGY LLC (US) 2019-04-24 EP disclosed
WO-2017222917-A1 ALIPHATIC PROLINAMIDE DERIVATIVES INCEPTION 4, INC. (US) 2017-12-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10730832-B2 Aliphatic prolinamide derivatives HTRA1, ALDH1A2, PREP CTSS 746/4885CTSK 1449/4885ACE 817/4885
US-20190330146-A1 ALIPHATIC PROLINAMIDE DERIVATIVES HTRA1, ALDH1A2, PREP CTSS 746/4885CTSK 1449/4885ACE 817/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.